GSK Plc
Open
$52.50
Prev. Close
$52.51
High
$52.52
Low
$52.43
Market Snapshot
$104.74B
13.3
1.60
$40.11B
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
emptyResult
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Recently from Cashu
U.S. Court Scrutinizes Vaccine Advisory Panel's Compliance with Federal Law and Public Health Governance
U.S. Government’s Vaccine Advisory Panel Actions Under Legal Scrutiny A federal court's recent commentary on the U.S. government's handling of vaccine recommendations signals a significant development…
GSK Expands Discounted Prescription Medications to Improve Accessibility and Affordability for Patients
GSK Expands Prescription Offerings, Enhancing Accessibility for Consumers GSK Plc makes significant strides in expanding its portfolio of discounted prescription medications, increasing the total numb…
GSK Expands Discounted Prescription Medications to Boost Accessibility and Affordability in Healthcare
GSK Expands Prescription Offerings to Enhance Accessibility and Affordability GSK Plc is poised to make significant advancements in the realm of affordable healthcare with its recent decision to expan…
GSK Achieves FDA Approval for Arexvy Vaccine in Infants, Enhancing Pediatric Respiratory Care
### GSK’s Pioneering Step in Pediatric Respiratory Care On Friday, GSK plc achieves a major milestone in respiratory health when the U.S. Food and Drug Administration (FDA) expands the approved age in…